FDA to pursue penance for practice violations

Share this article:
Medical product makers should be advised that FDA is planning to aggressively recommend misdemeanor prosecutions against responsible corporate executives for good manufacturing procedures (GMP) violations based on authority granted by the US Supreme Court in 1975, FDA deputy chief counsel for litigation Eric Blumberg told a Food and Drug Law Institute enforcement roundtable in April.

“Corporate officials should not be waiting for Warning Letters before addressing GMP issues at their firms,” he cautioned.

“This is not a negligence standard, but a strict liability standard, and so tell your clients to pay attention to their GMP reports and other information that is coming up to them,” Blumberg told his audience.

Increasing misdemeanor prosecutions was urged by a GAO report in March, which FDA commissioner Margaret Hamburg cited as part of her aggressive enforcement posture. In a letter to activist Senator Charles Grassley (R-IA), she said “criteria have been developed for consideration in selection of misdemeanor prosecution cases and will be incorporated into the revised policies and procedures that cover appropriate use of misdemeanor prosecutions.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...